You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Lead Compound Discovery from Engineered Analogs of Occidiofungin

    SBC: Sano Chemicals, Inc.            Topic: NIAID

    Project Summary Occidiofungin is a cyclic nonribosomally synthesized antifungal peptide with submicromolar fungicidal activity against a broad spectrum of fungi Occidiofungin is produced by the Gram negative bacterium Burkholderia contaminans From our structural characterization studies occidiofungin was determined to have a unique chemical composition Our studies have also revealed that occi ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  2. Towards a New Generation of Glycoengineered Pneumococcal Bioconjugate Vaccines

    SBC: VaxNewMO            Topic: NIAID

    PROJECT SUMMARY Pneumococcal pneumonia remains the leading cause of bacterial pneumonia in both children under years of age and adults over years of age The standard preventative therapy is the conjugate vaccine Prevnar which consists of an immunogenic carrier protein covalently attached to one of thirteen pneumococcal capsular polysaccharides Although Prevnar has significantly red ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  3. Aminooxyacetic Acid Prodrugs for Colon Cancer Therapy

    SBC: CBS THERAPEUTICS, INC.            Topic: 102

    ABSTRACT Recent studies of the applicants support the role of the endogenous gaseous biological mediator hydrogen sulfide H S in colorectal cancer In specific the selective upregulation of cystathionine synthase CBS and the subsequent production of H S in colonic cancer cells serves as a pro survival factor by stimulating tumor cell bioenergetics ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  4. Microparticulate mucosal vaccine for triple-negative breast cancer

    SBC: KIROMIC BIOPHARMA INC            Topic: 103

    ABSTRACT Triple negative breast cancerTNBCis a molecular subtype of breast cancer that is negative for expression of estrogen and progesterone receptors and human epidermal growth factor receptorHERClinicallyit is characterized by aggressive behaviordistinct patterns of metastasisand high rates of recurrence and mortalitySince TNBC tumor cells lack the necessary receptorsthe disease does not respo ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  5. Aspirin-PC for Chemoprevention of Colorectal Cancer

    SBC: PLx Opco Inc.            Topic: NCI

    ABSTRACT Colorectal cancerCRCis the third leading cause of cancer related deaths in the U SBased on numerous epidemiological studies and recent prospective clinical trialsthe use of daily aspirin is associated with a significant reduction in CRC incidencedeaths and metastatic spreadHoweverthe chronic use of this drug is limited due to the side effects of gastrointestinal bleeding ulceration in sus ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Oral Small Molecule STAT Inhibitor to Treat Cachexia in Chronic Kidney Disease

    SBC: StemMed, Ltd.            Topic: 400

    DESCRIPTION provided by applicant Chronic kidney disease CKD is a major public health problem in the US with an estimated prevalence of million patients enter hemodialysis or peritoneal dialysis programs yearly A serious complication in of patients with CKD is cachexia or muscle wasting which decreases quality of life and increases morbidity and mortality Unfortunately ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  7. Targeting Synaptotagmin to Prevent Airway Mucus Obstruction

    SBC: Exotect, LLC            Topic: NHLBI

    PROJECT SUMMARY Mucus dysfunction underlies the pathophysiology of a number of common respiratory diseases including asthma cystic fibrosis and chronic obstructive pulmonary disease COPD Asthma alone impacts of the US population resulting in considerable cost morbidity and occasional mortality caused by mucus hypersecretion Recently it was discovered that Synaptotagmin Syt regul ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Investigation of antibody drug conjugates of a novel target

    SBC: WNTRIX INC            Topic: NCI

    PROJECT SUMMARY Antibody drug conjugates ADCs are monoclonal antibodies mAbs that are covalently linked to cell killing drugs and have emerged as a major modality in anti cancer treatment This approach combines high specificity of mAbs against their antigen targets with highly potent cytotoxic drugs resulting in armed mAbs that deliver the payload drug to tumor cells with enriched levels ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  9. ErythroMer Nanoscale Bio Synthetic Red Cell Substitute

    SBC: KaloCyte Inc            Topic: NHLBI

    PROJECT SUMMARY There is need for an artificial oxygen O carrier to substitute for banked blood in settings where stored blood is unavailable pre hospital care transport austere environments undeveloped countries or undesirable transfusion risk exceeds benefit To address this need we developed ErythroMer EM a first in class nano cyte blood substitute EM is a deformable ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Enabling point of care molecular diagnostics by developing an adaptive PCR instrument and on demand kit reagents

    SBC: BIOVENTURES, INC            Topic: 172

    Because of its high sensitivity polymerase chain reaction PCR is the gold standard for the diagnosis of many infectious diseases but generally only implemented in well equipped laboratories One of the major roadblocks for expanding PCR to point of care markets is the lack of simple robust single tube PCR designs which preserve its laboratory based high sensitivity and specificity In this F ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government